BIOSIMILARS

BioFactura develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast^TM Biomanufacturing Platform, the optimal choice for bringing these drug to market with faster, lower cost, superior-quality manufacture.

The global biosimilars market is projected to grow from $4.5B in 2017 to over $23B by 2023 with a Compound Annual Growth Rate of >31%. Key drivers of future growth include the significant market share enjoyed by first generation monoclonal antibodies and their imminent patent expiries. In addition, the global market seems highly favorable due to increasing pressure felt by countries of all development stages to control the spiraling costs of healthcare and provide access to lifesaving medicines to their populations. BioFactura has identified a niche in the biosimilars market with current innovator revenues of over $24 billion. These blockbuster targets are optimally suited for development employing the company’s StableFast^TM technology.

BioFactura executed its first commercial biosimilar deal in 2013 and is developing a partner-selected biosimilar under a StableFast^TM platform license. In 2017-18, the Company is advancing its first in-house biosimilar drug candidates to the clinical stages. One internal program has reached the pre-IND stage with favorable initial biocomparability data.